B L Kemp
Impact in
- Biotechnology top 1%
- Cancer Research and Treatments
- Oncology top 5%
- Cancer-related Molecular Pathways
Papers in
-
- Cancer Genomics and Diagnostics 3
- Breast Cancer Treatment Studies 2
-
- Genetic factors in colorectal cancer 4
- Co-authors
- Fadlo Raja Khuri (7 shared papers)Scott Michael Lippman (3 shared papers)Waun Ki Hong (4 shared papers)Jonathan M. Kurie (4 shared papers)Waun K. Hong (1 shared paper)Lei Feng (1 shared paper)Reuben Lotan (1 shared paper)G. L. Walsh (4 shared papers)
- Journals
- Journal of Clinical Oncology (2 papers)JNCI Journal of the National Cancer Institute (2 papers)Lung Cancer (2 papers)Nature Medicine (1 paper)British Journal of Cancer (1 paper)
- Partner nations
- United States
In The Last Decade
B L Kemp
22 papers receiving 2.6k citations
Peers
Comparison fields: 5 of 99
- Biotechnology 487
- Oncology 1.1k
- Genetics 918
- Cancer Research 417
- Molecular Biology 1.3k
Countries citing papers authored by B L Kemp
This map shows the geographic impact of B L Kemp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B L Kemp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B L Kemp more than expected).
Fields of papers citing papers by B L Kemp
This network shows the impact of papers produced by B L Kemp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B L Kemp. The network helps show where B L Kemp may publish in the future.
Co-authors
The 25 scholars most cited alongside B L Kemp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1996 | 572 | |
| 2 | 1999 | 431 | |
| 3 | 1997 | 385 | |
| 4 | Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. | 2001 | 366 |
| 5 | 2000 | 275 | |
| 6 | Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. | 1998 | 104 |
| 7 | 1996 | 98 | |
| 8 | Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. | 2000 | 97 |
| 9 | Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. | 1999 | 93 |
| 10 | Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. | 1999 | 84 |
| 11 | Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. | 1998 | 65 |
| 12 | Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. | 2000 | 45 |
| 13 | C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers. | 2000 | 36 |
| 14 | 1999 | 29 | |
| 15 | TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. | 2001 | 25 |
| 16 | 2001 | 17 | |
| 17 | Calcofluor white stain for the detection of Pneumocystis carinii in transbronchial lung biopsy specimens: a study of 68 cases. | 1996 | 11 |
| 18 | 1999 | 11 | |
| 19 | Acute myelofibrosis--a leukemia of pluripotent stem cell. A report of three cases and review of the literature. | 1991 | 10 |
| 20 | Bivariate RNA and DNA content analysis in breast carcinoma: biological significance of RNA content. | 1996 | 5 |
About B L Kemp
B L Kemp is a scholar working on Cancer Research, Pathology and Forensic Medicine, Genetics, Biotechnology and Oncology, having authored 24 papers that have together received 2.8k indexed citations. Recurring topics across this work include Genetic factors in colorectal cancer (4 papers), Epigenetics and DNA Methylation (4 papers), Virus-based gene therapy research (4 papers), Cancer Genomics and Diagnostics (3 papers), Cancer Research and Treatments (3 papers), Cancer-related Molecular Pathways (3 papers), Breast Cancer Treatment Studies (2 papers) and Cancer-related gene regulation (2 papers). The work is most often cited by research in Biotechnology (487 citations), Oncology (1.1k citations), Genetics (918 citations), Cancer Research (417 citations) and Molecular Biology (1.3k citations). B L Kemp has collaborated with scholars based in United States. Frequent co-authors include Fadlo Raja Khuri, Scott Michael Lippman, Waun Ki Hong, Jonathan M. Kurie, Waun K. Hong, Lei Feng, Reuben Lotan, G. L. Walsh, Hong Wu and Li Mao. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Lung Cancer, Nature Medicine and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.